fenofibrate has been researched along with Colitis in 2 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of fenofibrate or GW0742 on the progression of colitis in C3H." | 7.74 | Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. ( Bajwa, PJ; Carson, MJ; Cong, Y; Elson, CO; Jeske, DR; Lee, JW; Lytle, C; Straus, DS, 2007) |
| "Fenofibrate treatment exacerbated inflammation and tissue injury in acute colitis, and this was dependent on PPARα activation." | 5.40 | PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. ( Bredell, BX; Brocker, CN; Fang, ZZ; Gonzalez, FJ; Jiang, C; Krausz, KW; Qi, Y; Shah, YM; Tanaka, N, 2014) |
| "The effect of fenofibrate or GW0742 on the progression of colitis in C3H." | 3.74 | Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. ( Bajwa, PJ; Carson, MJ; Cong, Y; Elson, CO; Jeske, DR; Lee, JW; Lytle, C; Straus, DS, 2007) |
| "Fenofibrate treatment exacerbated inflammation and tissue injury in acute colitis, and this was dependent on PPARα activation." | 1.40 | PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate. ( Bredell, BX; Brocker, CN; Fang, ZZ; Gonzalez, FJ; Jiang, C; Krausz, KW; Qi, Y; Shah, YM; Tanaka, N, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qi, Y | 1 |
| Jiang, C | 1 |
| Tanaka, N | 1 |
| Krausz, KW | 1 |
| Brocker, CN | 1 |
| Fang, ZZ | 1 |
| Bredell, BX | 1 |
| Shah, YM | 1 |
| Gonzalez, FJ | 1 |
| Lee, JW | 1 |
| Bajwa, PJ | 1 |
| Carson, MJ | 1 |
| Jeske, DR | 1 |
| Cong, Y | 1 |
| Elson, CO | 1 |
| Lytle, C | 1 |
| Straus, DS | 1 |
2 other studies available for fenofibrate and Colitis
| Article | Year |
|---|---|
PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.
Topics: Animals; Ceramides; Colitis; Colon; Fenofibrate; Hypolipidemic Agents; Mice; Mice, Inbred C57BL; PPA | 2014 |
Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice.
Topics: Age Factors; Animals; Cell Count; Chemokine CXCL10; Chemokines, CXC; Colitis; Crohn Disease; Disease | 2007 |